logo
China bans surgical treatment of Alzheimer's

China bans surgical treatment of Alzheimer's

Hindustan Times11-07-2025
China has banned surgical treatment of Alzheimer's disease after it was performed in about 400 hospitals over four years, saying there is a lack of high-quality medical evidence to support its safety and effectiveness. Alzheimer's disease – the leading cause of dementia - is a brain disorder that slowly destroys memory and thinking skills.(Pixabay)
The procedure, known as lymphatic-venous anastomosis (LVA), involves connecting the patient's lymph vessels to veins near the neck to speed up the flow and drainage of lymph fluid. The aim is to boost the removal of harmful brain proteins and slow the disease's progression.
The National Health Commission said it has recently learned that some medical institutions are conducting lymphaticovenous anastomosis, also known as LVA surgery, on patients diagnosed with Alzheimer's disease.
Following the commission's discovery, it conducted assessments on the procedure's safety and efficacy, the Commission said in a notice.
"Our evaluation concludes that there is a lack of evidence from preclinical studies in the use of LVA surgery for Alzheimer's disease treatment," it said, state-run China Daily reported on Friday.
"The procedure remains at an early stage of clinical research with its indications and contraindications yet to be clarified, and there is insufficient medical or health economic evidence attesting to its safety, efficacy and cost-effectiveness," the commission added.
Local health authorities are advised to instruct medical institutions to halt treating Alzheimer's disease with LVA surgery and guarantee proper follow-up care for affected patients.
"When sufficient preclinical evidence is collected, qualified medical institutions can carry out clinical studies under the full deliberation of ethics committees," it added.
The surgery has grown in popularity, particularly over the past year, since it was first performed in 2021 by a microsurgery expert from a private hospital in Hangzhou, in the eastern province of Zhejiang.
Based on publicly available information, an estimated 382 hospitals across almost all Chinese provinces had performed the procedure by the end of June, the Hong Kong-based South China Morning Post reported.
Alzheimer's disease – the leading cause of dementia - is a brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.
When the surgery first came to public attention, some Chinese doctors promoted it enthusiastically on social media, claiming it was 'effective for 60 to 80 per cent of patients', according to the Post report.
But it has also been met with scepticism, with some medical experts questioning its fundamental mechanism and long-term effectiveness.
Dr Fan Dongsheng, a professor in the neurology department at Peking University Third Hospital, warned that the scientific mechanism behind the treatment had not been well studied and was not convincing at present.
He told the Post that the reported improvements in patient symptoms were qualitative and not based on the accepted evaluation system.
Fan welcomed the government's decision to halt the treatment, calling it 'apparently problematic' that many hospitals, even small ones, performed the surgery extensively without solid evidence and had charged patients for it.
Users on the Chinese social media platforms, however, expressed their anxiety that diagnosed family members would no longer be able to receive the treatment.
'If the patient's family agrees, I think it's worth trying because some patients are in a really serious condition and their families are exhausted and desperate,' a person from northeastern Liaoning wrote.
One man said that his father, who was treated in March, had recovered well and could now recognise people and look after himself.
If surgery had the potential to improve patients' conditions, 'most families would choose to give it a try', he told the Post.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US targets knockoff weight-loss drugs
US targets knockoff weight-loss drugs

Time of India

time34 minutes ago

  • Time of India

US targets knockoff weight-loss drugs

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market—a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group—spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey—asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health , one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.

Bangladesh's Yunus Thanks India For Treating Dhaka Jet Crash Victims
Bangladesh's Yunus Thanks India For Treating Dhaka Jet Crash Victims

NDTV

timean hour ago

  • NDTV

Bangladesh's Yunus Thanks India For Treating Dhaka Jet Crash Victims

Dhaka: A delegation of 21 physicians and nurses from Singapore, China, and India met with Bangladesh's Chief Adviser Professor Muhammad Yunus on Sunday at the State Guest House Jamuna. The international medical teams are currently in Dhaka to provide specialised healthcare services to victims of the recent plane crash at Milestone School and College. During the meeting, Professor Muhammad Yunus expressed his heartfelt gratitude for the rapid response and medical support extended by the healthcare professionals. He commended their dedication and solidarity at a time of national crisis and emphasised the importance of international cooperation in emergency healthcare. "These teams have come not just with their skills, but with their hearts," said Professor Yunus. "Their presence reaffirms our shared humanity and the value of global partnerships in times of tragedy," he added. Chief Adviser thanks foreign medical teams for treating plane crash victims Dhaka, July 27, 2025: A delegation of 21 physicians and nurses from Singapore, China, and India met with Chief Adviser Professor Muhammad Yunus on Sunday at the State Guest House Jamuna. The… — Chief Adviser of the Government of Bangladesh (@ChiefAdviserGoB) July 28, 2025 The medical teams have been working tirelessly alongside local healthcare professionals to ensure critical treatment and trauma care for the injured, many of whom are young children. The Chief Adviser also acknowledged the swift diplomatic coordination that enabled the teams to arrive and begin their work without delay. He assured the visiting professionals of the government's full support in facilitating their mission. The Chief Adviser also urged the physicians to maintain long-term connections with Bangladesh, even virtually, for institutional collaboration, medical education exchange, and sustained engagement in capacity building and innovation in the healthcare sector. He emphasised that such partnerships could lay the foundation for lasting cooperation in public health and emergency preparedness. Health Adviser Nurjahan Begum thanked the physicians and nurses for extending their hand during this difficult time. Professor Sayedur Rahman, special assistant to the Chief Adviser for the Ministry of Health, said that many lives were saved as the foreign physicians rushed immediately. At the meeting, Prof Dr Md Nasir Uddin, Director, National Institute of Burn & Plastic Surgery (NIBPS), said that it was proven again that doctors are without borders. Ten members from Singapore, eight from China, and four from India attended the meeting. Among others, the Chinese Ambassador to Dhaka, Yao Wen, and the Singapore Head of Mission in Dhaka were also present at the meeting. On July 21, 2025, a Bangladesh Air Force training aircraft, specifically a Chinese-origin F-7 BGI fighter jet, crashed into the Milestone School and College campus in Dhaka 's Uttara neighbourhood. The crash resulted in the deaths of at least 27 people and injured over 170 others, mostly students. Bangladesh's interim government declared a national day of mourning on July 22, with flags flown at half-mast in all government offices and educational institutions.

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics
New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Mint

timean hour ago

  • Mint

New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics

Nephrocare Health Services Limited, widely recognized under the brand name NephroPlus, has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise ₹353.4 crore through an initial public offering (IPO). The Hyderabad-based company plans to use the proceeds to expand its network of dialysis clinics across India and repay outstanding debt, with the balance allocated to general corporate purposes. Advertisement The IPO will include a fresh issue of equity shares worth ₹353.4 crore and an offer-for-sale (OFS) of up to 1.27 crore equity shares by promoter and non-promoter shareholders. Among the OFS participants are Investcorp Private Equity Fund II, Healthcare Parent Limited, Edoras Investment Holdings Pte. Ltd., and 360 One Special Opportunities Fund. The company may also consider a pre-IPO placement of up to ₹70.6 crore, which would reduce the size of the fresh issue accordingly. Asia's Largest Dialysis Service Provider Established in 2009, NephroPlus has emerged as Asia's largest dialysis services provider and the fifth-largest globally in terms of the number of treatments performed in FY25, according to a Frost & Sullivan report. As of now, the company operates 447 clinics across 269 cities in 21 Indian states and 4 Union Territories, serving over 33,000 patients annually. NephroPlus commands more than 50 percent revenue market share in India's organised dialysis services market. Advertisement NephroPlus has also made a significant push into international markets. It currently operates 34 clinics in the Philippines, 5 in Nepal, 4 in Uzbekistan, and recently entered Saudi Arabia in a bid to tap the Middle East healthcare market. The company's promoters include Vikram Vuppala, BVP Trust (Bessemer Venture Partners), and Investcorp-affiliated entities. Proceeds to Fuel Domestic Expansion As per the DRHP, NephroPlus will allocate ₹129.1 crore from the fresh issue proceeds towards setting up new dialysis clinics in India, which aligns with its strategy to grow its domestic footprint. An additional ₹136 crore will be used to pre-pay or repay certain existing borrowings, enhancing the company's financial flexibility and improving its balance sheet. Advertisement In FY25, the company reported ₹755.8 crore in revenue from operations and a profit after tax of ₹67 crore, reflecting robust growth amid increasing demand for kidney care services. With chronic kidney disease (CKD) rising as the third fastest-growing cause of death globally, and diabetes and hypertension being its primary drivers, NephroPlus is well-positioned to benefit from secular health trends. ICICI Securities, Ambit Private Limited, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) are acting as Book Running Lead Managers (BRLMs) for the IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions. Advertisement

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store